Achieve A New Level Of Viral Vector Productivity With BalanCD HEK293 Perfusion A

Maximize viral vector production and accelerate your gene therapy development with BalanCD HEK293 Perfusion A, a chemically defined medium engineered for high-performance HEK293 cells in intensified and perfusion processes. This specialized formulation helps you overcome production limitations by supporting high cell densities while minimizing byproduct accumulation, leading to improved viral vector output and unparalleled productivity.

The medium is optimized for efficiency, allowing you to achieve a cell-specific perfusion rate (CSPR) of 25 pL/cell/day, thereby maximizing efficiency and reducing operational costs. It's designed for process flexibility, supporting both steady-state and intensified perfusion workflows for AAV and LV production, as demonstrated in HCD transfection and induction protocols. Engineered for seamless scalability and consistency, this medium can help ensure batch consistency and support regulatory compliance from small-scale systems to large bioreactor operations.

Break free from traditional batch limitations to reach new levels of AAV and LV productivity. Download the brochure below to view the data and discover how BalanCD HEK293 Perfusion A can transform your process.